NSCALE/KONTENA
22.7.2024 03:45:01 CEST | Business Wire | Press release
Nscale, a fully vertically integrated AI cloud platform, today announced the acquisition of Kontena, a leader in high-density modular data centres and AI Data Centre solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240721172829/en/
Joshua Payne, Founder and CEO, Nscale (Photo: Business Wire)
This acquisition marks a significant step forward in Nscale's mission to provide the infrastructure backbone to the growing generative AI market through cost-effective, high-performance solutions that unlock AI's full potential.
Jef Laurijssen, CEO of Kontena, commented: “Joining forces with Nscale provides us with an incredible opportunity to accelerate the development and deployment of cutting-edge Generative AI Data Centre solutions. Our combined expertise will enable us to deliver unparalleled value to our customers in the AI and HPC markets.”
Capitalising on Kontena’s innovative KONNECT ecosystem combined with Nscale’s extensive infrastructure capabilities, the two companies will deliver high-performance solutions. Kontena's flagship product, the EDGE data room, is a fully modular Generative AI Data Centre solution designed to meet the complex demands of advancing AI development. The EDGE data room is one of the world’s first modular solution deploying AI infrastructure on-premises and in remote locations, far quicker and at lower cost than traditional Tier 3 Data Centres.
Nscale’s acquisition of Kontena bolsters its commitment to sustainability. Kontena’s modular AI data centre solutions will enable Nscale to deliver faster and more cost-effective deployments for customers at its 100% renewable data centre sites in Norway and the US.
Joshua Payne, CEO of Nscale, commented: “The acquisition of Kontena allows Nscale to design, build, and deploy bespoke GPU clusters at scale for global Generative AI customers more quickly and more cost-effectively than the competition. Building Kontena into the Nscale value chain will allow us to deliver bespoke GPU superclusters and data centre builds for our large supercluster and hyperscale customers across Nscale’s 500MW of greenfield data centre capacity. This modular system can be deployed in Nscale’s data centres, on-premise, or at the edge to deliver unrivalled speed, performance, and efficiency on GenAI workloads. This is an important step towards our goal of vertical integration.”
This acquisition underscores Nscale’s dedication to driving innovation and delivering exceptional value to its customers. It follows Nscale’s recent announcement of a strategic partnership with Open Innovation AI, a leading GPU orchestration platform in MENA, targeting the deployment of 30,000 GPUs over the next 3 years, further solidifying its commitment to AI infrastructure and optimised workloads for global markets.
About Nscale
Nscale is a fully vertically integrated AI GPU Cloud provider delivering compute to the generative AI market at scale. Leveraging its 60MW renewable energy-powered data centre in Norway and a pipeline of over 500MW of greenfield data centres in the US. Nscale enables customers to run efficient and scalable AI training, fine-tuning, and compute-intensive workloads, supporting advanced AI research and development. Nscale provides the AI infrastructure backbone to the generative AI market.
About Kontena
Founded in 2018, Kontena specialises in high-density data centres and HPC solutions, combining innovation with practicality. The company recently collaborated with ElioVP and Bluesio to develop better and more innovative AI and HPC solutions.
For more information about Nscale’s AI & HPC solutions and the Kontena acquisition, visit nscale.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240721172829/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
